A randomized phase III study using 177Lu-PSMA-617 as a radioligand therapy in the treatment of patients with progressive, PSMA positive, metastatic castration resistant prostate cancer
The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-PSMA-617 in addition to best supportive/best standard of care versus patients treated with best supportive/best standard of care alone.
Key secondary objectives are an arm-to-arm comparison of the following:
- Radiographic progression-free survival (rPFS)
- Response Evaluation Criteria in Solid Tumors (RECIST) response
- Time to a first symptomatic skeletal event (SSE)
PI: Dr. Medhat Osman
Study Coordinator: Kelly Reno
This study is now closed to enrollment.